GNE myopathy is an inherited neuromuscular disorder caused by mutations in GNE (UDP-N-acetylglucosamine 2-epimerase/N-acetyl mannosamine kinase) gene catalyzing the sialic acid biosynthesis pathway. The characteristic features include muscle weakness in upper and lower extremities, skeletal muscle wasting, and rimmed vacuole formation. More than 200 GNE mutations in either epimerase or kinase domain have been reported worldwide. In Indian subcontinent, several GNE mutations have been recently identified with unknown functional correlation. Alternate role of GNE in various cellular processes such as cell adhesion, migration, apoptosis, protein aggregation, and cytoskeletal organization have been proposed in recent studies. We aim to understand and compare the effect of various GNE mutations from Indian origin on regulation of the cytoskeletal network. In particular, F-actin dynamics was determined quantitatively by determining F/G-actin ratios in immunoblots for specific proteins. The extent of F-actin polymerization was visualized by immunostaining with Phalloidin using confocal microscopy. The proteins regulating F-actin dynamics such as RhoA, cofilin, Arp2, and alpha-actinin were studied in various GNE mutants. The altered level of cytoskeletal organization network proteins affected cell migration of GNE mutant proteins as measured by wound healing assay. The functional comparison of GNE mutations will help in better understanding of the genotypic severity of the disease in the Indian population. Our study offers a potential for identification of therapeutic molecules regulating actin dynamics in GNE specific mutations.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12017-022-08711-4DOI Listing

Publication Analysis

Top Keywords

gne mutations
20
gne
11
cytoskeletal network
8
network proteins
8
cytoskeletal organization
8
f-actin dynamics
8
mutations
6
proteins
5
cytoskeletal
4
mutations cytoskeletal
4

Similar Publications

Mechanisms of immunotherapy resistance in small cell lung cancer.

Cancer Drug Resist

December 2024

Department of Medical Oncology, Yale School of Medicine, New Haven, CT 06510, USA.

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a poor prognosis. Although the addition of immunotherapy to chemotherapy has modestly improved outcomes, most patients rapidly develop resistance. Resistance to immunotherapy can be broadly categorized into primary resistance and acquired resistance, as proposed by the Society for Immunotherapy of Cancer (SITC) consensus definition.

View Article and Find Full Text PDF

Clinical features, mutation spectrum and factors related to reaching molecular diagnosis in a cohort of patients with distal myopathies.

J Neurol

January 2025

Neuromuscular Diseases Unit, Neurology Department, Hospital Universitari I Politècnic La Fe, Neuromuscular Reference Centre, ERN-EURO-NMD, Avenida de Fernando Abril Martorell 106, 46026, Valencia, Spain.

Background: Distal myopathies (MPDs) are heterogeneous diseases of complex diagnosis whose prevalence and distribution in specific populations are unknown.

Methods: Demographic, clinical, genetic, neurophysiological, histopathological and muscle imaging characteristics of a MPDs cohort from a neuromuscular reference center were analyzed to study their epidemiology, features, genetic distribution and factors related to diagnosis.

Results: The series included 219 patients (61% were men, 94% Spanish and 41% sporadic cases).

View Article and Find Full Text PDF

Introduction: GNE-myopathy is a distal myopathy with adult-onset and initial involvement of anterior leg compartment. A founder effect has been demonstrated for some patients from several large cohorts in different countries.

Methods: In this study, we investigated the allele frequency of the c.

View Article and Find Full Text PDF

Rare genetic disorders are low in prevalence and hence there is little or no attention paid to them in the mainstream medical industry. One of the ultra-rare neuromuscular disorders, GNE myopathy is caused due to biallelic mutations in the bifunctional enzyme, GNE (UDP N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase). It catalyses the rate-limiting step in sialic acid biosynthesis.

View Article and Find Full Text PDF

A pilot trial for efficacy confirmation of 6'-sialyllactose supplementation in GNE myopathy: Randomized, placebo-controlled trial.

Mol Genet Metab

January 2025

Department of Neurology, Pusan National University School of Medicine, Busan, Republic of Korea; Department of Neurology and Biomedical Research institute, Pusan National University Yangsan Hospital, Gyeongsangnam-do, Republic of Korea. Electronic address:

Article Synopsis
  • GNE myopathy is a rare genetic muscle disorder that leads to weakness in the ankles and muscle degeneration, caused by mutations in the GNE gene that reduce sialic acid production.
  • A clinical trial tested a supplement, 6'-sialyllactose (6SL), at doses of 3g and 6g to see if it could improve muscle strength and health, revealing better outcomes in muscle strength and reduced degeneration with the higher dose.
  • The latest study involved 11 participants to compare 6SL with a placebo group over 48 weeks, finding no major differences in muscle strength but a significant degeneration in muscle fat measured by MRI, indicating muscle health issues, particularly in the placebo group.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!